Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israele, Tel Aviv-Giaffa
Fredi Aviv
34 anni di esperienza
Clinica certificata da :
| Israele | Turchia | Austria | |
| Immunoterapia con Keytruda (Pembrolizumab) | da $9,800 | da $3,300 | da $15,000 |
| Chemioterapia per carcinoma mammario | da $22,500 | da $1,200 | da $15,000 |
| Chemioterapia | da $2,400 | da $2,430 | da $2,500 |
| Terapia biologica | - | da $5,500 | da $20,000 |
| Radioterapia per il cancro colorettale | - | da $7,000 | da $12,000 |
Il medico è un ostetrico e ginecologo altamente esperto con oltre 25 anni nel campo. Specializzandosi in Medicina della Riproduzione in Ostetricia e Ginecologia, il medico è esperto in trattamenti come Inseminazione Intrauterina (IUI), Procedura di Induzione dell'Ovulazione, Perforazione Ovarica e gestione delle Valvole Uretrali.<\/p>
Il medico ha completato una borsa di studio presso il Ronald O Perelman e Claudia Cohen Centre, possiede un diploma dall'Irlanda e ha conseguito un MBBS presso l'Università di Mysore, India.<\/p>
Il medico è certificato dal consiglio in Medicina Interna, Ematologia e Oncologia Medica. Il percorso professionale include una residenza presso la State University of New York a Brooklyn e una borsa di studio in Ematologia e Oncologia presso il New York Medical College, Westchester Medical Center.<\/p>
Con un forte impegno nel campo medico, il medico ha pubblicato oltre 30 articoli scientifici e ha contribuito a un capitolo di un libro di testo medico. La competenza è ulteriormente dimostrata dall'esecuzione di diverse centinaia di trapianti di cellule staminali, evidenziando l'esperienza in questo settore.<\/p>
Il medico è il capo del Dipartimento di Oncoematologia e Oncologia Pediatrica presso l'Ospedale Pediatrico Dana Dwek. Specializzandosi in trapianti di midollo osseo e sangue del cordone ombelicale per bambini, il medico ha effettuato oltre 300 trapianti. Con una forte presenza accademica, il medico ha pubblicato 50 articoli e presentato 40 relazioni in varie conferenze mediche. Il medico è membro dell'Associazione Americana di Ematologia e della Società Israeliana di Emato-oncologia Pediatrica, e ha praticato presso il City of Hope Hospital di Los Angeles e in vari centri medici in Israele.<\/p>
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Israel reports exceptional Hodgkin lymphoma success rates, including a 100% one-year survival for patients using innovative chemo-biologic protocols. Clinics maintain a 90% average oncology success rate. Specialized centers achieve a 95% complete response rate using advanced chemotherapy and targeted biological therapy combinations.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky prioritize rapid adaptation based on diagnostic data. Experts like Dr. Abraham Avigdor use PET-CT scans after just two chemotherapy cycles to measure response. If the disease persists, they immediately switch to salvage therapies or clinical trials. This proactive approach explains why Israeli centers report higher remission rates than the global average.
Patient Consensus: Patients note that fertility preservation is a routine part of the process and usually covered. Many emphasize how the clean, well-run environment at clinics like Sourasky makes their treatment journey easier.
Israel offers advanced medical innovations like home-grown CAR-T cell therapy and TIL immunotherapies for hematologic cancers. Facilities like Sheba Medical Center and Sourasky Medical Center provide targeted drug treatments including Keytruda. Precise PET/CT-based prognostics help doctors tailor protocols for Hodgkin lymphoma and other complex conditions.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center maintain a 90% success rate by integrating research directly into clinical practice. Dr. Fredi Aviv has over 30 years of experience specifically in oncohematology clinical trials at this facility. Patients benefit from doctors who personally develop the protocols they administer.
Patient Consensus: Patients note it is important to choose JCI-accredited hospitals that offer all-inclusive support for smooth communication. Many highlight that local CAR-T options provide accessible alternatives to expensive international commercial drugs.
Israel is a global leader in Hodgkin lymphoma care. Major centers like Sheba Medical Center and Sourasky Medical Center offer advanced treatments. These include CAR T-cell therapy and bone marrow transplants. Facilities maintain Joint Commission International accreditation and high success rates.
Bookimed Expert Insight: While Sheba is famous for Newsweek rankings, Sourasky serves 1,800,000 patients yearly with 2,200 doctors. This high volume allows specialists like Dr. Fredi Aviv to focus only on blood cancers. Choosing these high-capacity centers often provides faster access to multidisciplinary teams.
Patient Consensus: Patients note that major centers like Sheba provide faster access to PET scans and immunotherapy than many Western hospitals. They emphasize the importance of English-speaking coordinators who help navigate the system without bureaucracy.
Standard Hodgkin lymphoma treatment in Israel typically lasts between 3 and 12 months. This duration includes 6 cycles of chemo for early stages. Cases involving CAR-T cell therapy or bone marrow transplants require 30 days of inpatient monitoring. All treatment plans involve regular PET-CT scans for progress tracking.
Bookimed Expert Insight: While chemotherapy cycles are predictable, advanced immunotherapy like CAR-T cell therapy offered at Sheba Medical Center follows a faster timeline but requires precise logistical coordination. Patients should account for a 2-week cell manufacturing period before the actual infusion. Data shows that clinics like Sourasky achieve a 90% success rate by strictly adhering to these treatment intervals without delays.
Patient Consensus: Patients note that low blood counts or minor infections can easily extend the timeline by 1 to 3 months. Many emphasize the importance of starting fertility preservation before the first cycle begins to avoid missing the window for future family planning.
Israeli medical centers provide structured support for international Hodgkin's lymphoma patients. Services include medical coordination, Jolnt Commission International (JCI) accredited safety protocols, and visa assistance. Facilities like Sheba Medical Center or Sourasky Medical Center offer dedicated international departments to manage logistics, including airport transfers and language interpretation.
Bookimed Expert Insight: Israeli hospitals often bundle extensive diagnostics into treatment packages to ensure accuracy. For instance, Sheba Medical Center includes PET/CT scans and specialist consultations within their bone marrow transplant programs. This approach eliminates the need for patients to arrange separate appointments, saving significant time during urgent treatment phases.
Patient Consensus: Patients note it's important to have a coordinator who speaks your language fluently. They often mention that having transportation pre-arranged by the clinic significantly reduces stress when arriving in a new country.